Paul F. Lizzul Sells 1,500 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. The sale was disclosed in a filing with the SEC, which is available through this link.

AnaptysBio Stock Down 7.3 %

ANAB stock opened at $32.34 on Thursday. The firm has a market capitalization of $887.09 million, a PE ratio of -5.27 and a beta of -0.29. AnaptysBio, Inc. has a twelve month low of $13.36 and a twelve month high of $41.31. The stock’s 50 day moving average is $35.75 and its 200-day moving average is $28.06.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The company had revenue of $10.97 million for the quarter, compared to the consensus estimate of $25.85 million. On average, equities research analysts anticipate that AnaptysBio, Inc. will post -6.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Great Point Partners LLC increased its position in shares of AnaptysBio by 9.2% during the fourth quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock valued at $20,927,000 after acquiring an additional 82,648 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of AnaptysBio during the 1st quarter worth approximately $420,000. Octagon Capital Advisors LP purchased a new position in AnaptysBio in the fourth quarter valued at approximately $2,570,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of AnaptysBio during the 1st quarter valued at $1,221,000. Finally, First Light Asset Management LLC increased its holdings in AnaptysBio by 56.4% in the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after acquiring an additional 446,372 shares during the last quarter.

Analyst Ratings Changes

ANAB has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a research report on Wednesday, August 14th. JPMorgan Chase & Co. upped their target price on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, Truist Financial upped their target price on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $50.30.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.